[go: up one dir, main page]

Serino et al., 2006 - Google Patents

Meningococcal diseases: From genomes to vaccines

Serino et al., 2006

Document ID
3753995238334201779
Author
Serino L
Bambini S
Comanducci M
Pizza M
Rappuoli R
Publication year
Publication venue
Drug Discovery Today: Therapeutic Strategies

External Links

Snippet

Valuable information can be obtained from the complete genome sequence of a microorganism, which has changed the approach to vaccine development. The new approach, called 'Reverse Vaccinology'was first applied for Neisseria meningitidis, allowed …
Continue reading at www.sciencedirect.com (other versions)

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL, OR TOILET PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/02—Bacterial antigens
    • A61K39/095—Neisseria
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL, OR TOILET PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/60—Medicinal preparations containing antigens or antibodies characteristics by the carrier linked to the antigen
    • A61K2039/6031—Proteins
    • A61K2039/6037—Bacterial toxins, e.g. diphteria toxoid [DT], tetanus toxoid [TT]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL, OR TOILET PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/02—Bacterial antigens
    • A61K39/105—Delta proteobacteriales, e.g. Lawsonia; Epsilon proteobacteriales, e.g. campylobacter, helicobacter
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by the preceding groups
    • G01N33/48—Investigating or analysing materials by specific methods not covered by the preceding groups biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/53—Immunoassay; Biospecific binding assay
    • G01N33/569—Immunoassay; Biospecific binding assay for micro-organisms, e.g. protozoa, bacteria, viruses
    • G01N33/56911—Bacteria
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL, OR TOILET PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/51—Medicinal preparations containing antigens or antibodies comprising whole cells, viruses or DNA/RNA
    • A61K2039/52—Bacterial cells; Fungal cells; Protozoal cells
    • A61K2039/522—Bacterial cells; Fungal cells; Protozoal cells avirulent or attenuated
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL, OR TOILET PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/51—Medicinal preparations containing antigens or antibodies comprising whole cells, viruses or DNA/RNA
    • A61K2039/53—DNA (RNA) vaccination
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/195—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from bacteria
    • C07K14/22—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from bacteria from Neisseriaceae (F)
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL, OR TOILET PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/545—Medicinal preparations containing antigens or antibodies characterised by the dose, timing or administration schedule
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/195—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from bacteria
    • C07K14/24—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from bacteria from Enterobacteriaceae (F), e.g. Citrobacter, Serratia, Proteus, Providencia, Morganella, Yersinia
    • C07K14/245—Escherichia (G)

Similar Documents

Publication Publication Date Title
Giuliani et al. Measuring antigen-specific bactericidal responses to a multicomponent vaccine against serogroup B meningococcus
Jódar et al. Development of vaccines against meningococcal disease
Serruto et al. Genome-based approaches to develop vaccines against bacterial pathogens
Hollingshead et al. An overview of Neisseria meningitidis
Christodoulides et al. Novel approaches to Neisseria meningitidis vaccine design
JP2006521782A (en) Multiple variants of meningococcal protein NMB1870
Serruto et al. Biotechnology and vaccines: application of functional genomics to Neisseria meningitidis and other bacterial pathogens
Bai et al. Genetic shifts of Neisseria meningitidis serogroup B antigens and the quest for a broadly cross-protective vaccine
Vogel et al. Vaccine development against Neisseria meningitidis
Sun et al. Identification of novel antigens that protect against systemic meningococcal infection
Serino et al. Meningococcal diseases: From genomes to vaccines
Wheeler et al. Exploring the proteome of meningococcal outer membrane vesicle vaccines
Bernardini et al. The analysis of Neisseria meningitidis proteomes: Reference maps and their applications
Knaust et al. Genome-based vaccines
US20090297547A1 (en) Pharmaceutical composition containing the nmb0938 protein
Vermont et al. Meningococcal serogroup B infections: a search for a broadly protective vaccine
Boccadifuoco et al. A combined approach to assess the potential coverage of a multicomponent protein-based vaccine
US20100129387A1 (en) Pharmaceutical composition containing the nmb0606 protein
US20070128230A1 (en) Protein nmb0928 and use thereof in pharmaceutical formulations
Suker et al. Prospects offered by genome studies for combating meningococcal disease by vaccination
Cafardi et al. Bacterial genomes and vaccine design
US20100172931A1 (en) Pharmaceutical Composition Containing the NMB1796 Protein
US20090208521A1 (en) Pharmaceutical compositions containing protein nma0939
Viviani Dissection of the protective response elicited by the DOMV component of the 4CMenB vaccine
Riddell et al. Vaccines against meningococcal disease: current and future technologies